November 4, 2014 | Peregrine Ventures sold its 30 percent stake in Neovasc to Fidelity for $12 million, selling 2 million of their 6.7 million company shares, at $6 per share. Peregrine’s holdings in Neovasc, a company that manufactures, develops and markets cardiovascular products, are worth approx. $27.5 million, with Peregrine holding on to 4.7 million of its shares in Neovasc. Neovasc was created through a merger deal led by Peregrine Ventures in 2008, in which two of Peregrine’s companies, Neovasc and B-Ballon merged with the publicly traded Canadian company Medical Ventures Corporation.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments